These director sales are routine post-vesting diversification and carry no informational signal. The strong Q2 earnings beat and raised fundamentals remain the dominant narrative. Monitor for any C-suite insider activity or changes in the 10b5-1 trading plan schedule, but no action is warranted from this cluster.
Drugs in focus
REGN drug pipeline →Dupixent
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- Time to market
- Already approved and commercialized since 2017
- Next catalyst
- None dated
What to watchDupixent is Regeneron's most important revenue driver, generating collaboration revenue that rose 14-18% YoY in recent quarters. Investors should watch for the STYLE 1/STYLE 2 Phase 3 topline readouts for Lichen Simplex Chronicus (mid-2026) as the next label-expansion catalyst, but the main investor focus should be on Dupixent's patent cliff, earliest key patents begin expiring around 2027-2031, which will determine whether Regeneron can defend its ~$17.8B+ franchise against biosimilar entry.
- ● EYLEA HD 4/10 Approved Named in filing
- ● Libtayo 4/10 Approved Named in filing
- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ● Evkeeza 4/10 Approved
- 11 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 13 $805.97entry
- T+1 · 3mo ago −0.31%α −0.11% · $803.48
- T+5 · 3mo ago +2.56%α +4.53% · $826.64
- T+20 · 2mo ago −3.04%α −1.29% · $781.49
- T+60 · 11d ago +12.21%α +17.68% · $904.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Regeneron directors sold a combined $960K in open-market sales on August 10, 2026, following the exercise of stock options. The sales are small relative to the $82.1B market cap (0.001%) and are typical post-vesting diversification by non-executive directors. The cluster occurred 14 days after a strong Q2 earnings beat (revenue +17% YoY, EPS 40% above consensus), suggesting routine portfolio management rather than a bearish signal.
Key Financial Metrics
Key Facts
- Two directors sold a total of 1,200 shares for $960K on August 10, 2026
- Sales were open-market transactions following option exercises (non-cash exercises of $0 and $287K/$301K)
- Total sales represent ~0.001% of REGN's $82.1B market cap, well below the 0.1% materiality threshold
- Cluster occurred 14 days after Q2 2026 earnings beat (revenue $4.29B, +17% YoY; non-GAAP EPS $14.29 vs consensus $10.20)
- No C-suite executives participated; only two independent directors
Financial Impact
Insider sales of $960K represent 0.001% of market cap, trivial and non-material
Risk Factors
- No material risk identified from this cluster; the trivial size and director-only composition make it non-informative
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-REGN-1786612390669 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers